A Proximity Extension Assay (PEA)-based method for quantification of bevacizumab

Mikačić, Ivana; Belužić, Robert; Plavljanić, Đuro

doi:10.1016/j.vascn.2018.02.008

Cited by 5 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PEA has been widely applied in non-clinical biomedical research to decipher minute protein concentrations in minute sample volumes. In contrast, current studies have seen more applications of PEA in exploring both diagnostic markers and inflammation key components ( 60 , 61 ).…”

Section: Recent Developments In Proteomics Technologiesmentioning

confidence: 99%

Psoriasis to Psoriatic Arthritis: The Application of Proteomics Technologies

Tan

Yao

et al. 2021

Front. Med.

View full text Add to dashboard Cite

Psoriatic disease (PsD) is a spectrum of diseases that affect both skin [cutaneous psoriasis (PsC)] and musculoskeletal features [psoriatic arthritis (PsA)]. A considerable number of patients with PsC have asymptomatic synovio-entheseal inflammations, and approximately one-third of those eventually progress to PsA with an enigmatic mechanism. Published studies have shown that early interventions to the very early-stage PsA would effectively prevent substantial bone destructions or deformities, suggesting an unmet goal for exploring early PsA biomarkers. The emergence of proteomics technologies brings a complete view of all involved proteins in PsA transitions, offers a unique chance to map all potential peptides, and allows a direct head-to-head comparison of interaction pathways in PsC and PsA. This review summarized the latest development of proteomics technologies, highlighted its application in PsA biomarker discovery, and discussed the possible clinical detectable PsA risk factors in patients with PsC.

show abstract

Section: Recent Developments In Proteomics Technologiesmentioning

confidence: 99%